Jiangxi Kvvit Pharmaceutical is paying an undisclosed amount up front, plus potential milestones and royalties, to Merz Therapeutics to acquire the rights to develop and commercialize Merz’s Inbrija levodopa dry powder inhaler in mainland China, Hong Kong, and Macao, the companies announced. Kvvit will be responsible for clinical development and regulatory submissions seeking approval for Inbrija for the treatment of OFF episodes in Parkinson’s disease in those markets and for commercialization if the product is approved.
Merz acquired Inbrija from Acorda Therapeutics in 2024. The DPI is Inbrija has been approved for the Parkinson’s disease indication in the US since December 2018 and in Europe since 2019.
Merz President, Region International Markets, Andrea von der Lippe commented, “We are pleased to partner with Kvvit to potentially bring Inbrija to people living with Parkinson’s disease in Greater China. Kvvit’s local development and commercial capabilities combined with Merz’s experience with Inbrija create a strong foundation to expand access to an additional treatment option for patients experiencing OFF episodes.”
Kvvit VP Yang Lizhen said, “Kvvit is always committed to providing outstanding services for human health. Based in China and with a global perspective, it hopes to offer patients more valuable and innovative treatment plans for neurological diseases. Based on this cooperation opportunity with Merz for the development, registration, and subsequent commercialization of Inbrija, we will closely cooperate with medical professionals to facilitate its rational application in clinical practice.”
Read the Merz Therapeutics and Kvvit press release
